2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Molecular Testing, Omics Technologies, Bioinformatics, Computational Biology, Emerging Technologies, Profiling, Treatment Considerations, Combination Therapy, Drug Development, Therapy Sequence, Biological Therapies, Antibody Therapy, Transplantation, Checkpoint Inhibitor, Immunotherapy, Non-Biological Therapies, Chemotherapy, Adverse Events, Artificial Intelligence (AI), Deep Learning, Machine Learning, Biological Processes, Apoptosis, Pathogenesis, Genomics, Hematopoiesis, Immune Mechanism, Metabolism, Molecular Biology, Multi-Systemic Interactions, Clinical Practice (Health Services and Quality), Practice Models, Value, Diseases, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Measurable Residual Disease, Research, Fundamental Science, AML, APL, Translational Research, MDS, MPN, CMML, Clinical Research, Epidemiology, Health Outcomes Research, Health Disparities Research, Real-World Evidence, Survivorship, Study Population, Human, Adult
PAPER

3475 Molecularly informed progression kinetics to guide surveillance and maintenance duration in acute myeloid leukemia

Anas Odeh, MD, Emily C Zabor, PhD2, Ameed Bawwab, MD3, Lana Khatib4, Girahnaz Baloch, MD5, Moath Albliwi, MD6, Jessica El-Asmar, MD, MPH7, Yang Wang8, David Bosler, MD9, Akriti G Jain, MD, FACP10, John Carlos Molina, MD, MEd11, Abhay Singh, MD, MPH12, Aaron T. Gerds, MD, MS13, Sudipto Mukherjee, MD, PhD, MPH14, Claudio Brunstein, MD, PhD15, Anjali Sunder Advani, MD16, Hetty Carraway, MD, MBA17, Moaath Mustafa Ali, MD, MPH18
1 Cleveland Clinic, Cleveland, Ohio, United States
2 Cleveland Clinic Taussig Cancer Institute, Cleveland, Ohio, United States
3 Cleveland Clinic, Cleveland, Ohio, United States
4 Cleveland Clinic, Cleveland, Ohio, United States
5 Cleveland Clinic, Cleveland, Ohio, United States
6 Cleveland Clinic, Cleveland, Ohio, United States
7 Cleveland Clinic Taussig Cancer Institute, Cleveland, Ohio, United States
8 Cleveland Clinic Taussig Cancer Institute, Cleveland, Ohio, United States
9 Cleveland Clinic Diagnostics Institute, Cleveland, Ohio, United States
10 Cleveland Clinic Taussig Cancer Institute, Cleveland, Ohio, United States
11 Cleveland Clinic Taussig Cancer Institute, Cleveland, Ohio, United States
12 Cleveland Clinic Taussig Cancer Institute, Cleveland, Ohio, United States
13 Cleveland Clinic Taussig Cancer Institute, Cleveland, Ohio, United States
14 Cleveland Clinic Taussig Cancer Institute, Cleveland, Ohio, United States
15 Cleveland Clinic Taussig Cancer Institute, Cleveland, Ohio, United States
16 Cleveland Clinic Taussig Cancer Institute, Cleveland, Ohio, United States
17 Cleveland Clinic Taussig Cancer Institute, Cleveland, Ohio, United States
18 Department of Hematology and Medical Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland, Ohio, United States

Background

Despite high complete remission rates with contemporary therapies, relapse remains the leading cause of treatment failure and death in acute myeloid leukemia (AML). ELN 2022 and related frameworks stratify whether a patient is likely to relapse but are not designed to estimate when; post-remission surveillance intervals and treatment durations therefore remain largely uniform across biologically distinct subgroups. We characterized progression kinetics across recurrent cytogenetic and molecular subgroups to build a molecularly informed framework for relapse timing.

Methods

We retrospectively studied 1,017 adults treated for AML at Cleveland Clinic Ohio centers between 01/2015 and 01/2025. Data included demographics, comorbidities, AML subtypes, cytogenetics & molecular features, treatment responses, and follow-up data. Cytogenetic and molecular abnormalities of interest were specified a priori. Progression was defined as relapse or refractory disease, measured from the date of AML diagnosis; patients non-evaluable for response were censored at their non-evaluable date, and death without progression was treated as a competing risk. The cumulative incidence of progression (CIF) was estimated with the Aalen-Johansen estimator at 3-month intervals through 12 months and 6-month intervals thereafter; estimates were suppressed when fewer than 10 patients remained at risk. A landmark analysis restricted to patients’ progression-free at 12 months estimated CIF at 6, 12, and 24 months after the landmark. Incidence density (events per 100 person-months) was calculated within each interval. Subgroups were not mutually exclusive and analyses were descriptive rather than adjusted.

Results

Median age at diagnosis was 66 years (IQR 56-73), 54% were male, and 89% were white. Karyotype was normal in 37% and abnormal low-/intermediate-/high-risk in 6.6%/24%/28%; complex karyotype was present in 22% and monosomal karyotype in 16%. Frequent mutations included DNMT3A (26%), NPM1 (23%), TET2 (21%), RUNX1 (16%), TP53 (16%), and FLT3-ITD (10%).

Early progression differed markedly by subgroup. Three-month CIF ranged from 0% for t(8;21) and 2.4% for CEBPA to 15.4% for monosomal karyotype, 13.9% for -5/del(5q), 11.9% for TP53, and 11.6% for complex karyotype. Rank order changed over time: by 12 months, CIF was highest for del(20q) (40.5%), WT1 (38.1%), CEBPA (37.6%), -5/del(5q) (37.2%), and monosomal karyotype (36.3%), and lowest for non-ITD FLT3 (10.5%), t(8;21) (12.1%), NPM1 (20.7%), and inv(16) (21.4%).

Incidence density revealed distinct patterns over time. Adverse cytogenetic groups front-loaded risk, peaking at 3-6 months (monosomal 9.53, complex 7.26, TP53 7.22 events/100 person-months) and declining after 12 months (1.49-3.09). Other subgroups peaked late: CEBPA rose from 0.87 (0-3 months) to 9.19 (9-12 months) with no subsequent events, and IDH1 peaked at 6-9 months (7.30). Core-binding factor AML accrued risk gradually rather than early, with inv(16) CIF of 4.8% at 6 months, 21.4% at 12 months, and 36.3% at 24 months. FLT3-ITD peaked early (5.82 at 3-6 months) and fell to 1.32 after 12 months, whereas non-ITD FLT3 remained below 2.0 throughout.

Among patients progression-free at 12 months, risk over the following 24 months remained appreciable for SRSF2 (36.4%), NRAS (31.3%), complex karyotype (31.1%), RUNX1 (30.8%), ASXL1 (30.5%), and IDH1 (28.8%), but was lower for FLT3-ITD (20.4%), NPM1 (19.2%), DNMT3A (18.9%), and WT1 (16.6%). TP53 risk appeared largely exhausted by the landmark, with a 6-month post-landmark CIF of 5.0% among the 10 patients still at risk. Beyond 24 months from diagnosis, incidence density fell below 1 event per 100 person-months in most subgroups.

Conclusions

The timing of AML progression, not only its probability, varied substantially across molecular and cytogenetic subgroups. Distinct progression phenotypes emerged, including early high-risk disease (monosomal/complex karyotype, TP53), delayed progression (core-binding factor AML, CEBPA, IDH1), and persistent late risk (SRSF2, NRAS, RUNX1, ASXL1). Progression incidence declined to low levels after 24 months in most subgroups. These subgroup-specific kinetics extend current molecular risk stratification beyond predicting whether relapse occurs to estimating when it is most likely, providing a framework to individualize MRD surveillance, optimize trial follow-up, and identify patients in whom monitoring may be intensified, prolonged, or safely de-escalated.
Anas Odeh, MD: No relevant conflicts of interest to declare.